‘Explosive demand’ for primate research drives Alpha Genesis expansion in Europe

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/ananaline)
(Image: Getty/ananaline)
Alpha Genesis is investing more than $2m in its European operations to help meet a demand for Zika, Ebola, and flu vaccine development.

The Alpha Genesis Primate Research Center (AGPRC), the research division of Alpha Genesis Incorporated (AGI), is expected to “take on” additional European business commitments, according to the company – as it looks to continue expansion efforts.

Greg Westergaard, PhD, AGI president and CEO, said the investment of more than $2m in staff and infrastructure has allowed the company “to make significant inroads across this highly competitive area.” 
The expansion will support demand for new vaccines to combat diseases such as Zika, Ebola, and new flu strains, Westergaard told Outsorucing-Pharma.com.

“The ability to conduct such research in Europe is more constrained than in the US, and Alpha Genesis employs scientists with specialized skills in high-demand research areas,”​ he added.

According to the company, it will conduct contract research projects with rhesus and cynomolgus macaques to accommodate “explosive demand for work with nonhuman primates across Europe.”

Westergaard expects demand for its research services to increase by an average of 20-25% per year over the next decade.

“Primate research is integral to the development of new cures for human diseases and is of great benefit to people of all ages throughout the world,”​ he said.

AGI said a number of its customers “will move an increased portion of their studies to AGI’s European outreach operation in 2019.”

According to the company, the move is expected to see AGI's European research business increase by more than 75% percent to more than $4m per annum over the next 18 months.

The company in 2016 invested $2m​ to expand its South Carolina facility and add 30 jobs to support its primate breeding capabilities

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more